Digital-Chemosensory Training for Substance Use Disorders
This study is testing a new approach called EDITOR (Enhanced Digital-Chemosensory-Based Olfactory Training for Remote Management of Substance Use Disorders) for people with substance use disorders, including opioid, alcohol, cocaine, and methamphetamine use disorders. EDITOR uses a device that stimulates your sense of smell and your brain (orbitofrontal cortex) to help with recovery. We are comparing EDITOR to a similar device (CBOT) and usual care to see if EDITOR helps people stay in treatment longer. You may be able to join if you are 18-80 years old and have a moderate or severe substance use disorder. The study aims to enroll 300 adults.
- Study design
- This interventional study plans to enroll 300 adult participants. It compares EDITOR to CBOT and usual care to see which is more effective.
- What's involved
- Not specified in the trial record.
- Compensation
- Not stated in the trial record.
- Follow-up
- The study will measure how long participants stay in treatment at 14 days, 28 days, and 8 weeks after starting.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
Enhanced Digital-Chemosensory-Based Olfactory Training for Remote Management of Substance Use Disorders
At a glance
Conditions
Where it's being run
3 sites across 2 statesStudy leadership
- Charles Nwaokobia · PRINCIPAL_INVESTIGATOR · Evon Medics LLC
- Evaristus Nwulia, MD · PRINCIPAL_INVESTIGATOR · Evon Medics LLC
- Tanya Alim, MD · PRINCIPAL_INVESTIGATOR · Howard University
- Edwin Chapman, MD · PRINCIPAL_INVESTIGATOR · Clinics of Dr. Edwin Chapman at MHDG
- Marc Fishman, MD · PRINCIPAL_INVESTIGATOR · Maryland Treatment Centers, Inc.
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
What this trial measures
- Retention in SUD treatmentBaseline to day 14
3-month retention in SUD treatment, is defined as missing two consecutive clinic visits after completing the first two weeks of SUD treatment; the rationale is to allow for buprenorphine (BUP) dose stabilization in those with opiate use disorder (OUD). Investigators found that missing two visits strongly correlated with self-reported relapse, positive drug urine screen, and non-adherence to the buprenorphine. Ascertainment of retention is simply by tracking clinic visits and electronic record of the health visit.
- Retention in SUD treatmentBaseline to day 28
3-month retention in SUD treatment, is defined as missing two consecutive clinic visits after completing the first two weeks of SUD treatment; the rationale is to allow for buprenorphine (BUP) dose stabilization in those with opiate use disorder (OUD). Investigators found that missing two visits strongly correlated with self-reported relapse, positive drug urine screen, and non-adherence to the buprenorphine. Ascertainment of retention is simply by tracking clinic visits and electronic record of the health visit.
- Retention in SUD treatmentBaseline to 8 weeks
3-month retention in SUD treatment, is defined as missing two consecutive clinic visits after completing the first two weeks of SUD treatment; the rationale is to allow for buprenorphine (BUP) dose stabilization in those with opiate use disorder (OUD). Investigators found that missing two visits strongly correlated with self-reported relapse, positive drug urine screen, and non-adherence to the buprenorphine. Ascertainment of retention is simply by tracking clinic visits and electronic record of the health visit.
- Retention in SUD treatmentBaseline to three months
3-month retention in SUD treatment, is defined as missing two consecutive clinic visits after completing the first two weeks of SUD treatment; the rationale is to allow for buprenorphine (BUP) dose stabilization in those with opiate use disorder (OUD). Investigators found that missing two visits strongly correlated with self-reported relapse, positive drug urine screen, and non-adherence to the buprenorphine. Ascertainment of retention is simply by tracking clinic visits and electronic record of the health visit.
- SUD Relapse RateBaseline to day 7
Relapse is defined as presence of self-reported repeat (i.e., 2 or more) specific substance use after the first week, and/or presence of positive urine drug test for opiates. Ascertainment of relapse is through: 1. survey question administered weekly, inquiring how many days in the past 1 week did the subject use drugs or alcohol; the dates of substance use; and the quantity (or dose) of drugs used; and 2. biochemical verification of drug use from urine samples collected and tested every two weeks.
- SUD Relapse RateBaseline to day 14
Relapse is defined as presence of self-reported repeat (i.e., 2 or more) specific substance use after the first week, and/or presence of positive urine drug test for opiates. Ascertainment of relapse is through: 1. survey question administered weekly, inquiring how many days in the past 1 week did the subject use drugs or alcohol; the dates of substance use; and the quantity (or dose) of drugs used; and 2. biochemical verification of drug use from urine samples collected and tested every two weeks.
- SUD Relapse RateBaseline to day 28
Relapse is defined as presence of self-reported repeat (i.e., 2 or more) specific substance use after the first week, and/or presence of positive urine drug test for opiates. Ascertainment of relapse is through: 1. survey question administered weekly, inquiring how many days in the past 1 week did the subject use drugs or alcohol; the dates of substance use; and the quantity (or dose) of drugs used; and 2. biochemical verification of drug use from urine samples collected and tested every two weeks.
- SUD Relapse RateBaseline to 8 weeks
Relapse is defined as presence of self-reported repeat (i.e., 2 or more) specific substance use after the first week, and/or presence of positive urine drug test for opiates. Ascertainment of relapse is through: 1. survey question administered weekly, inquiring how many days in the past 1 week did the subject use drugs or alcohol; the dates of substance use; and the quantity (or dose) of drugs used; and 2. biochemical verification of drug use from urine samples collected and tested every two weeks.
- SUD Relapse RateBaseline to three months
Relapse is defined as presence of self-reported repeat (i.e., 2 or more) specific substance use after the first week, and/or presence of positive urine drug test for opiates. Ascertainment of relapse is through: 1. survey question administered weekly, inquiring how many days in the past 1 week did the subject use drugs or alcohol; the dates of substance use; and the quantity (or dose) of drugs used; and 2. biochemical verification of drug use from urine samples collected and tested every two weeks.
- SUD engagementBaseline to day 14
SUD engagement is the proportion of people treated at baseline who complete the first two weeks of treatment.